1. Home
  2. ATAT vs FOLD Comparison

ATAT vs FOLD Comparison

Compare ATAT & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Atour Lifestyle Holdings Limited

ATAT

Atour Lifestyle Holdings Limited

HOLD

Current Price

$42.40

Market Cap

5.9B

ML Signal

HOLD

Logo Amicus Therapeutics Inc.

FOLD

Amicus Therapeutics Inc.

HOLD

Current Price

$14.24

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATAT
FOLD
Founded
2013
2002
Country
China
United States
Employees
N/A
N/A
Industry
Hotels/Resorts
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9B
3.1B
IPO Year
2022
2007

Fundamental Metrics

Financial Performance
Metric
ATAT
FOLD
Price
$42.40
$14.24
Analyst Decision
Strong Buy
Buy
Analyst Count
5
8
Target Price
$46.16
$29.79
AVG Volume (30 Days)
1.5M
14.8M
Earning Date
11-25-2025
11-04-2025
Dividend Yield
1.08%
N/A
EPS Growth
25.36
N/A
EPS
1.48
N/A
Revenue
$1,276,315,178.00
$598,704,000.00
Revenue This Year
$37.61
$21.49
Revenue Next Year
$23.33
$18.25
P/E Ratio
$28.26
N/A
Revenue Growth
36.24
21.28
52 Week Low
$21.50
$5.51
52 Week High
$43.17
$14.36

Technical Indicators

Market Signals
Indicator
ATAT
FOLD
Relative Strength Index (RSI) 58.79 91.17
Support Level $40.40 $10.64
Resistance Level $43.17 $14.36
Average True Range (ATR) 1.32 0.34
MACD -0.05 0.39
Stochastic Oscillator 71.24 97.25

Price Performance

Historical Comparison
ATAT
FOLD

About ATAT Atour Lifestyle Holdings Limited

Atour Lifestyle Holdings Ltd is an upper-midscale hotel chain in China. The company derives revenues from franchise and management fees from its manachised hotels and sales of hotel supplies to manachised hotels, Operations of leased hotels, and sales of retail products. The company has one operating segment, which is the Atour Group.

About FOLD Amicus Therapeutics Inc.

Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

Share on Social Networks: